Chiba, Japan

Ichirou Kitada

This inventor holds 1 USPTO granted patent. Top assignee: Yamanouchi Pharmaceutical Company Ltd.. Active years: 1992.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1992

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ichirou Kitada: Innovator in Biochemical Patents

Introduction

Ichirou Kitada is a notable inventor based in Chiba, Japan. He has made significant contributions to the field of biochemistry, particularly through his innovative patents. His work focuses on the development of novel compounds that have potential applications in medicine and biotechnology.

Latest Patents

Ichirou Kitada holds a patent for a galactosamine substitute of poly-.omega.-substituted-L-glutamic acid. This invention involves a polypeptide that includes a recurring unit represented by a specific formula. The polypeptide is characterized by the substitution of part or all of the peptide with an .omega.-galactosamyl-L-glutamic acid residue. This innovative approach could lead to advancements in therapeutic applications.

Career Highlights

Ichirou Kitada is associated with Yamanouchi Pharmaceutical Company Ltd., where he has been able to apply his expertise in biochemistry. His work has contributed to the company's research and development efforts, particularly in the area of pharmaceutical innovations.

Collaborations

Throughout his career, Ichirou Kitada has collaborated with esteemed colleagues such as Toshihiro Akaike and Megumi Kunou. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their respective fields.

Conclusion

Ichirou Kitada's contributions to biochemistry through his patent on galactosamine substitutes highlight his role as an innovator in the pharmaceutical industry. His work continues to inspire advancements in medical research and applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…